
    
      This study is a double-blind, placebo-controlled single ascending dose safety and
      tolerability study. Approximately 32-56 subjects with clinical diagnosis of ALS according to
      modified El Escorial criteria are planned to receive a single dose of study drug, NP001.
    
  